Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brightgene Bio-medical Technology Co (SHSE:688166) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Brightgene Bio-medical Technology Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥16,887 Mil.
Brightgene Bio-medical Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥153 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co EV-to-EBIT Related Terms
Brightgene Bio-medical Technology Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co EV-to-EBIT Chart
SHSE:688166 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co EV-to-EBIT vs Biotechnology Industry
Brightgene Bio-medical Technology Co's current Enterprise Value is ¥17,416 Mil.
Brightgene Bio-medical Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥153 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a EV-to-EBIT of 114.19 as of Sep. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Brightgene Bio-medical Technology Co and its competitors. This is 60% above median its historical median of 71.32. Over the past decade, Brightgene Bio-medical Technology Co's EV-to-EBIT has ranged from 30.15 to 453.61. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #345 out of 366 companies in the Biotechnology industry, placing it in the top 94.3%.
Is Brightgene Bio-medical Technology Co's EV-to-EBIT too high?
Brightgene Bio-medical Technology Co's current EV-to-EBIT of 114.19 is 60% above median its 10-year median of 71.32. Over the past 10 years, this metric has ranged from a low of 30.15 to a high of 453.61. The Biotechnology industry median EV-to-EBIT is 15.55. Brightgene Bio-medical Technology Co's value of 114.19 is 634.3% above this industry median. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #345 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #345 out of 366 companies for EV-to-EBIT. This places Brightgene Bio-medical Technology Co in the lower half of its industry. The industry median EV-to-EBIT is 15.55. Brightgene Bio-medical Technology Co's value of 114.19 is 634.3% above this benchmark. Historically, Brightgene Bio-medical Technology Co's own EV-to-EBIT has ranged from 30.15 to 453.61 over the past decade. While the company's 10-year median is 71.32 vs. the industry median of 15.55, Brightgene Bio-medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brightgene Bio-medical Technology Co's current EV-to-EBIT of 114.19 is 634.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Brightgene Bio-medical Technology Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brightgene Bio-medical Technology Co's current EV-to-EBIT is 114.19, which is 60% above median its own 10-year median of 71.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥42.29, compared to a current price of ¥36.47 — trading 13.8% below its estimated fair value. The current EV-to-EBIT is 114.19, which is 60% above median its 10-year median of 71.32 and 634.3% above the Biotechnology industry median of 15.55. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current EV-to-EBIT is 114.19 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥36.47 is trading 13.8% below its estimated GF Value™ of ¥42.29.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
EV-to-EBIT: 114.19 (60% above median its 10-year median of 71.32)
GF Value™: ¥42.29 vs. price of ¥36.47 (13.8% below fair value)
Industry Position: 634.3% above the Biotechnology median (#345 of 366)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
